Transition Therapeutics: Phillip Frost's Opko Health completes $60M acquisition of biopharmaceutical firm

Opko Health announced Wednesday that it has completed its acquisition of Toronto-based biopharmaceutical company Transition Therapeutics. A final transaction figure was not disclosed, but it was reported in June that the deal was valued at approximately $60 million. "We are pleased to complete the acquisition of Transition Therapeutics as it provides us with two late-stage drug candidates, each of which holds exceptional market opportunity and has direct synergies with our clinical development...